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Abstract
A major roadblock to the application of bioartificial livers is the need for a human liver cell line that displays a high and
broad level of hepatic functionality. The human bipotent liver progenitor cell line HepaRG is a promising candidate in this
respect, for its potential to differentiate into hepatocytes and bile duct cells. Metabolism and synthesis of HepaRG
monolayer cultures is relatively high and their drug metabolism can be enhanced upon treatment with 2% dimethyl
sulfoxide (DMSO). However, their potential for bioartificial liver application has not been assessed so far. Therefore, HepaRG
cells were cultured in the Academic Medical Center bioartificial liver (AMC-BAL) with and without DMSO and assessed for
their hepatic functionality in vitro and in a rat model of acute liver failure. HepaRG-AMC-BALs cultured without DMSO
eliminated ammonia and lactate, and produced apolipoprotein A-1 at rates comparable to freshly isolated hepatocytes.
Cytochrome P450 3A4 transcript levels and activity were high with 88% and 37%, respectively, of the level of hepatocytes.
DMSO treatment of HepaRG-AMC-BALs reduced the cell population and the abovementioned functions drastically.
Therefore, solely HepaRG-AMC-BALs cultured without DMSO were tested for efficacy in rats with acute liver failure (n=6).
HepaRG-AMC-BAL treatment increased survival time of acute liver failure rats ,50% compared to acellular-BAL treatment.
Moreover, HepaRG-AMC-BAL treatment decreased the progression of hepatic encephalopathy, kidney failure, and ammonia
accumulation. These results demonstrate that the HepaRG-AMC-BAL is a promising bioartificial liver for clinical application.
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Introduction
Acute liver failure (ALF) and acute-on-chronic liver failure are
severe clinical syndromes with mortality rates as high as 80%
[1,2]. Clinically, the syndromes present as a severe impairment of
liver function with hepatocellular necrosis, leading to hepatic
encephalopathy (HE), systemic inflammation, and multi-organ
failure. Despite the progress made in supportive care, liver
transplantation is often the only cure, increasing the survival rates
to over 80% [3,4]. However, liver transplantation is limited by the
scarcity of donor organs.In the US, about 20% of the patients with
severe liver failure (MELD score .30) who are on the waiting list
for liver transplantation die while waiting for a donor liver [5].
Bioartificial livers (BALs) have been developed to bridge these
patients to liver transplantation or liver regeneration [6]. BALs
typically comprise a bioreactor that is loaded with a biocomponent
with hepatic functionality that is connected to the patient’s
circulation. BAL systems, based on animal hepatocytes, are
efficacious in animal models of ALF [7,8]. However, due to
xenotransplantation-related risks, there is an urgent need for BAL
systems relying on human biocomponents [9].
This human biocomponent should compensate for the loss of
liver function and counteract concomitant pathology, including
hepatic encephalopathy (HE), inflammation, and multi-organ
failure. Pathophysiologically, reduced conversion of ammonia into
urea and amino acids, as well as reduced drug-metabolizing
activity, lead to accumulating levels of ammonia and several other
neurotoxins (e.g. mercaptans and endogenous benzodiazepines),
which all play an important role in the progression of HE [10]. In
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lactate elimination and the synthesis of blood proteins, e.g.
apolipoprotein A-1, are associated with serious complications,
such as lactic acidosis and progressive inflammation [11,12].
Successful BAL therapy should therefore include the adequate
replacement of all these functions.
The human hepatoma cell line HepaRG may be a promising
candidate for BAL application. HepaRG is a bipotent liver
progenitor cell line that differentiates into two distinct cell
populations upon reaching confluence, optionally followed by
treatment with 2% dimethyl sulfoxide (DMSO): 1) hepatocyte-like
cells that self-organize into clusters; and 2) cluster-neighboring cells
that express biliary markers [13,14]. Cultured on monolayer,
DMSO treatment leads to unparalleled high drug-metabolizing
activity with expression of cytochrome P450 (CYP) 3A4 confined
to the hepatocyte-like clusters [13–15].
Recently, we showed that HepaRG monolayer cultures
exhibited high metabolic and synthetic properties in the absence
of DMSO: the levels of galactose and ammonia elimination,
apolipoprotein A-1 production, and transcription of albumin
reached those of freshly isolated [16]. Interestingly, DMSO
treatment promoted cell death and thereby reduced cell-mass
more than 2-fold. In addition, DSMO treatment repressed hepatic
functions originally present in cluster-neighboring regions. None-
theless, the drug-metabolizing properties were superior in DMSO-
treated cultures, with transcript levels of CYP2B6 and CYP3A4
reaching 61% and 69% of the levels in human liver, whereas the
expression levels of these genes reached only 10% and 11%,
respectively, in the 2DMSO cultures. Taken together, HepaRG
cells display a high and broad hepatic functionality promising for
BAL application, when HepaRG cultures in the absence and
presence of DMSO are being combined.
Therefore, the aim of this study was to characterize the hepatic
functionality of the HepaRG cell line differentiated in the AMC-
BAL, that was developed by our group, both in the presence and
absence of DMSO, and to test the efficacy of this HepaRG-AMC-
BAL in a rat model of ALF [17].
Materials and Methods
Monolayer Cell Culture and Cell Isolation
HepaRG cells, isolated from a human liver tumor [13], were
cultured in Hyperflasks (Corning, New York, U.S.) in HepaRG
medium without DMSO [13] for large scale expansion. Cultures
were maintained at 37uC in a humidified atmosphere (95% air,
5% CO2). Culture medium was refreshed every 3 to 4 days. We
passaged the cells every 2 weeks with a split ratio of 1:6 (cell
density 610
5 cells/cm
2) using a Accutase (Innovative Cell
Technologies, San Diego, U.S.), Accumax (Innovative Cell
Technologies), and phosphate-buffered saline (Fresenius Kabi
GmbH, Bad Homburg vor der Ho ¨he, Germany) mix of 2:1:1 (v/
v/v). Prior to loading the AMC-BAL, the isolated cells were
centrifuged at 506 g for 5 min and washed 26 with HepaRG
medium. Per AMC-BAL, a suspension of 2 mL cell pellet
(approximately 750 million cells) in 9 mL HepaRG medium (=
pre-BAL suspension) was prepared.
AMC-BAL Culture
We used the laboratory-scale version of the third generation
AMC-BAL with an internal volume of 9 mL [17,18]. AMC-BALs
were loaded with the pre-BAL suspension as described previously
and from then on oxygenated with a mixture of 40% oxygen, 55%
nitrogen, and 5% carbon dioxide (v/v/v) [18]. The cells were
allowed to attach to the AMC-BAL’s matrix for 3 hours.
Thereafter, AMC-BALs were continuously perfused with
500 mL recirculating HepaRG culture medium supplemented
with 1 mM N-carbamoyl-L-glutamate (Sigma Aldrich, St. Louis,
U.S.). This latter compound was added to increase the ammonia
to urea conversion rate ,2-fold [16]. Every 3 to 4 days, all culture
medium was refreshed. We generated 2DMSO BALs by
culturing for 14 days on HepaRG culture medium supplemented
with 1 mM N-carbamoyl-L-glutamate without DMSO (n=5 to
11). The +DMSO BALs were generated by adding a 14-day
culture period on HepaRG culture medium supplemented with
1 mM N-carbamoyl-L-glutamate and with 2% DMSO (n=5 to
11) (Sigma Aldrich). At termination of the cultures, the BAL
content was lyzed to determine DNA content [19].
Determination of Bioactive Mass and Cell Death
To determine bioactive mass and cell death during AMC-BAL
culture, we analyzed pre-BAL suspensions and total lysates of
BALs for DNA content (n=3 to 6). In addition aspartate
aminotransferase (AST) and lactate dehydrogenase (LDH) activity
were determined in pre-BAL suspensions and in the culture
medium perfused through the bioreactor as described previously
(n=3 to 6) [19].
Quantitative Reverse Transcription-polymerase Chain
Reaction
We analyzed gene expression levels of samples of matrix
containing cells (T-bags) harvested from 2DMSO and +DMSO
BALs as described [19,20]. Transcript levels were normalized for
18S ribosomal RNA and expressed as a percentage of the mean of
two human liver samples. These liver samples derived from two
female patients, aged 40 and 41 years, with liver adenoma and no
elevated liver damage, after obtaining written informed consent.
The patients were not on medication and had no history of drug/
alcohol abuse. The procedure was in accordance with the ethical
standards of the institutional committee on human experimenta-
tion (protocol number 03/024) and the Helsinki Declaration of
1975.
BAL Function Tests
Bioreactors were first flushed with 30 mL test medium, followed
by a 24-hour period of recirculation with 100 mL of test medium
(HepaRG culture medium supplemented with 1 mM N-carbam-
oyl-L-glutamate, 125 mM testosterone (Sigma Aldrich), 1.5 mM
15NH4Cl (Sigma Aldrich), 2 mM L-lactate (Sigma Aldrich), and
2.75 mM D-galactose (Sigma Aldrich)). Samples (1 mL) were
taken at 0.5, 1, 2, 8 and 24 hours of recirculation and analyzed for
concentrations of ammonia, urea,
15N-urea, 6b-hydroxytestoster-
one, apolipoprotein A-1, and lactate as described [16,19,21,22].
Function parameter rates were determined by calculating the
changes in concentration in medium per hour per BAL and per
mg DNA harvested from the BALs.
Histology
Complete transverse 8 mm sections of formaline-fixed and
paraplast-embedded BALs were stained with hematoxylin
(VWR, Amsterdam, The Netherlands) and azofloxine (Sigma
Aldrich) as described [20].
Rat Model of Complete Liver Ischemia (CLI)
All procedures were conducted in accordance with the
institutional guidelines of the Animal Ethical Committee of the
AMC (protocol number 101190). We used a rat model of CLI to
induce ALF principally as described [7]. Briefly, male Wistar rats
HepaRG Cells Effective in a Bioartificial Liver
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50 mg of the antibiotic rifaximin (Sigma Aldrich) per kg body-
weight, suspended in water, per gavage once a day starting from day
5 pre-CLI to standardize intestinal flora. At day 3 pre-CLI the rats
were given an end-to-side portocaval shunt and the animals were
allowed to recover for 3 days to prevent bleeding from the shunt
anastomosis. For CLI, the hepatic artery was ligated under
isoflurane anesthesia and the rats received 8 to 16 IU per 100 g
bodyweight of the low molecular weight heparin dalteparine
(Pfizer, New York, U.S.) intravenously (t=0). Subsequently, the
rats were allowed to wake up and move around freely. Blood
glucose levels were maintained between 5 and 10 mM in all rats.
In every experiment, a second rat was used as a blood donor. To
this end, blood was drawn intracardially under isoflurane
anesthesia and mixed with a citrate-phosphate-dextrose solution
(Sanquin, Amsterdam, The Netherlands) in a 7:1 (v/v) blood to
solution proportion.
The Extracorporeal BAL System
We used a modified version of the extracorporeal BAL system
(Fig. 1) used by Flendrig et al. [7]. Modifications included: 1)
incorporating two, instead of one, plasmapheresis modules with an
effective length of 105 mm, an internal diameter of 8 mm, 80
Plasmaphan capillaries with 0.47 mm max. pore size, and a total
membrane surface of 90 cm
2 (Membrana GmbH, Wuppertal,
Germany); 2) priming of the plasma and BAL circuits of the
extracorporeal BAL system with plasma expander Elohaes
(Fresenius Kabi GmbH) without any supplements; 3) priming of
the blood circuit with healthy rat citrate-phosphate-dextrose-
blood; 4) supplementing the rat with a 20% dextrose infusion and
a saline infusion to a total of 2.0 mL/h to prevent hypoglycemia
and dehydration; 5) no continuous dalteparine infusion was given;
and 6) placing the extracorporeal BAL system in a temperature-
controlled cabinet at 37uC.
Animal Study Design
Rats were treated with an acellular AMC-BAL (n=9) (control
group) or with a 2DMSO HepaRG-AMC-BAL (n=8) (experi-
mental group). Exclusion criteria were: incomplete recovery from
anesthesia, .6 mL intraperitoneal bleeding post mortem, hemo-
globin levels ,9.0 g/dL, pulmonary embolism or stroke, air
embolism, and/or incomplete CLI as determined at autopsy. All
these exclusion criteria were chosen to secure reproducible
progression of ALF until death, without additional confounding
factors, e.g. .50% blood loss. In the control group, the first 3 rats
were excluded because of excessive (.9 mL) intraperitoneal
bleeding. In the experimental group, 3 rats had to be excluded
because of pulmonary embolism (thrombus formation in the
tubings), air embolism (empty bubble catcher), and incomplete
recovery after anesthesia. Notably, these events were unrelated to
BAL treatment or the learning curve of the model. At t=30
minutes, the rat was connected to the extracorporeal BAL system
including the AMC-BAL. Blood samples of 0.1–0.5 mL were
taken hourly and were replaced with healthy rat citrate-phosphate-
dextrose-blood to avoid excessive blood loss. HepaRG-AMC-
BALs were refreshed at t=6 hours to prevent deterioration of
BAL function due to ALF plasma toxicity. To prevent dilution by
this procedure, the new BAL was filled with plasma harvested
from the preceding BAL. The rat was disconnected from the
extracorporeal BAL system after death and autopsy was
performed. CLI was considered complete if the liver remained
uncolored upon post-mortem injection of a methylene blue
solution into the carotid artery, while the caval vein was clamped
both inferior and superior to the liver. We did not use
histopathology to validate CLI, as this method could miss small
remnants of vascularized liver tissue (e.g. by anatomic variation).
Animal Study Endpoints
The primary endpoint in this study was survival time, and
secondary endpoints were the clinical HE grading score (Table 1),
the blood ammonia and the plasma creatinine concentrations.
Furthermore, plasma alanine aminotransferase and AST levels,
hemoglobin levels, and blood glucose levels were analyzed as
described [7].
Statistical Analysis
We compared differences between the two experimental groups
using unpaired Student’s t-tests. Logrank tests were used to
compare survival data. SPSS 16.0.1 (SPSS Inc., Chicago, USA)
was used for statistical analysis. Prism version 4.01 (GraphPad
Prism Inc, San Diego, USA) was used for graphical presentation of
the data. Data are expressed as means 6 standard deviations.
Significance was reached if P,0.05.
Results
Proliferation, Cell Death, and Morphology of HepaRG
Cells Cultured in the AMC-BAL
The total DNA content at the time of loading (pre-BAL) did not
significantly differ from the total DNA content of the HepaRG-
AMC-BAL after 14 days of culturing without DMSO (2DMSO
group) (Fig. 2A). However, in HepaRG-AMC-BALs cultured for
an additional 14 days in the presence of 2% DMSO (+DMSO
group), the total DNA content decreased to 25% compared to the
pre-BAL and the 2DMSO groups.The total AST and LDH
content per BAL were 134668 and 3126100 U, respectively. In
the 2DMSO BALs, AST and LDH leakage were limited, with
respectively 0.16 and 0.30 U per BAL per hour, representing a
leakage of 2.8% and 2.3%, respectively, of their total content per
day (Fig. 2B, C). In the +DMSO BALs, AST and LDH leakage
per BAL were comparable to the 2DMSO BALs. At a cellular
level however, this implied a 3- to 4-fold increase in cell damage in
the +DMSO BALs compared to the 2DMSO BALs.
The matrix of different cross sections of the 2DMSO BALs was
completely filled with cells that adhered to the polyester fibers
(Fig. 3A, C). Notably, few gas capillaries were present, as they
easily detach from the slides during the staining procedure. In
contrast to the 2DMSO BALs, the matrix of the +DMSO BALs
contained many large acellular areas. A closer inspection of these
acellular areas revealed the presence a web-like network of fibers
typical for extracellular matrix (Fig. 3B, D).
These observations support the hypothesis that DMSO induced
cell death in HepaRG-AMC-BALs. In addition, the functionality
of 2DMSO HepaRG-AMC-BAL remained stable until at least 28
days, excluding the possibility that prolonged culture itself (and not
DMSO) could be responsible for the observed cell death (data not
shown).
In vitro Functionality of HepaRG-AMC-BALs
Transcript levels of CYP3A4 and of transcription regulators
hepatic nuclear factor 4a (nuclear receptor subfamily 2, group A,
member 1), and pregnane X receptor (nuclear receptor subfamily
1, group I, member 2) in the 2DMSO BALs were comparable to
human liver (Table 2), and only hepatic nuclear factor 4a
transcript levels further increased 1.5-fold upon addition of
DMSO. Interestingly, CYP3A4 transcript levels had reached
88% of human liver after 14 days culture without DMSO.
Notably, CYP3A4 transcript levels reached only 10% of human
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+DMSO cultures [16]. The CYP3A4 transcript levels increased
1.6-fold to 143% of human liver in +DMSO BALs. In contrast to
CYP3A4, transcript levels of the urea cycle genes carbamoylpho-
sphate synthetase and arginase 1 were only 29% and 16%,
respectively, of human liver in 2DMSO BALs, and decreased
both dramatically to only 1%, upon addition of DMSO.
Glutamine synthetase transcript levels were 405% of human liver
in 2DMSO BALs, and also decreased around two-fold upon
addition of DMSO.
Overall hepatic functionality in 2DMSO BALs was high
(Fig. 4), with ammonia elimination (Fig. 4A), 6b-hydroxytestoster-
one production, a marker for CYP3A4 activity (Fig. 4D),
apolipoprotein A-1 production (Fig. 4E), and lactate consumption
rates (Fig. 4F) being between 37% and 148% of a porcine
hepatocyte BAL (historical control) or freshly isolated human
hepatocytes cultured in monolayer [16,18]. Urea production was
still limited with 23% of a porcine hepatocyte BAL. Moreover,
analysis of the mass-enriched urea fraction revealed that 27% of
Figure 1. A schematic presentation of the extracorporeal bioartificial liver circuit.
doi:10.1371/journal.pone.0038778.g001




2 Poor posture control; decreased motor activity; poor posture control
3 No spontaneous righting reflex; severe ataxia; diminished response to pain
4 No righting reflex on pain stimulus
5 Deep coma; no reaction on pain stimulus
6 Death
doi:10.1371/journal.pone.0038778.t001
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ammonia (Fig. 4B, C).
DMSO addition dramatically decreased the hepatic function-
ality per BAL for all hepatic functions measured. DMSO also
reduced some hepatic functions at the cellular level, i.e. a 4-fold
decreased conversion of ammonia into urea (Fig. 4C) and a switch
from lactate consumption to lactate production (Fig. 4F). There-
fore, we concluded that 2DMSO HepaRG-AMC-BALs outper-
form +DMSO HepaRG-AMC-BALs in in vitro functionality and
viability, and therefore only these were tested in ALF rats.
Efficacy of the HepaRG-AMC-BAL in Rats with ALF
Two groups of rats underwent CLI: the experimental group,
treated with a 2DMSO HepaRG-AMC-BAL and the control
group, treated with an acellular AMC-BAL. Within 45 min after
induction of ALF, all animals had recovered from anesthesia. All
rats developed ALF as measured by an increase in plasma alanine
aminotransferase and AST levels to .15000 U/L and
.20000 U/L, respectively, with no differences between both
groups. Post-mortem, CLI was confirmed in all rats using the
methylene blue test.
The average survival time in the experimental group was 47%
longer than in the control group (14.361.9 versus 9.761.0 hours;
P=0.001;n=5and6,respectively)(Fig.5A).Weobservedagradual
progression of HE in all rats (Fig. 5B). However, progression was
significantly slower in the experimental group compared to the
control group as measured by the time point at which the rats
reached the easily observable HE score of 4 for the first time
(4.761.2 versus 9.261.6 hours, respectively; P=0.005; n=6)
(Fig. 5C). In all rats blood ammonia levels gradually increased to
millimolarlevels,butagain,slowerintheexperimentalgroupthanin
Figure 2. Proliferation and cell death in 2DMSO and +DMSO
HepaRG-AMC-BALs. Proliferation and cell death in the BALs was
measured by their total DNA content (A), and leakage of AST (B) and
LDH (C). AST and LDH leakage are expressed ‘per BAL’ (white bars; read
along the left y-axis) and ‘per mg of DNA’ (grey bars; read along the
right y-axis). Values are expressed as means 6 standard deviations
(n=3 to 6). Significance: * P,0.05 versus pre-BAL suspensions (A) or
2DMSO BALs (B, C).
doi:10.1371/journal.pone.0038778.g002
Figure 3. HA stainings of cross sections of 2DMSO (A, C) and
+DMSO HepaRG-AMC-BALs (B, D). Full transverse sections (A, B)
show the spirally wound matrix layers with the gas capillaries (arrows)
positioned in between. Details of the matrix (C, D) show the polyester
matrix fibers (arrowheads) with HepaRG cells, and the web-shaped
extracellular matrix in acellular areas in the matrix (D). Bars: 200 mm (A,
B) and 20 mm (C, D).
doi:10.1371/journal.pone.0038778.g003





Hepatocyte nuclear factor 4a 77631 11668 1.56q 0.048
Pregnane X receptor 103628 181698 1.86q 0.066
Cytochrome P450 3A4 88642 143618 1.66q 0.076
Carbamoyl phosphate synthetase 29671 602 9 6Q 0.000
Arginase 1 16611 1611 6 6Q 0.031
Glutamine synthetase 4056202 224691 1.86Q 0.014
Transcript levels are indicated as % of mean mRNA levels of two human liver
samples and normalized for 18S ribosomal RNA. The change in transcript levels
of +DMSO BALs relative to the 2DMSO BALs are indicated with q for
upregulation and Q for downregulation. Abbreviations: DMSO, dimethyl
sulfoxide; AMC-BAL, Academic Medical Center-bioartificial liver. Values are given
as means 6 standard deviations (n=5 to 6). P values refer to 2DMSO versus
+DMSO BALs.
doi:10.1371/journal.pone.0038778.t002
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concentration at t=8 hours (Fig. 5D). Plasma creatinine levels were
measuredtoassessrenaldysfunctionthatdevelopssecondarytoALF
as part of multi-organ failure. In the experimental group, plasma
creatinine levels increased slower, resulting in 57% lower concen-
tration at t=8 hours (Fig. 5E).
Discussion
In this study, we demonstrated that the HepaRG-AMC-BAL
displays a broad and a high level of hepatic functionality in vitro,a s
measured by the elimination of ammonia, production of urea,
production of 6b-hydroxytestosterone, consumption of lactate, and
synthesis of apolipoprotein A-1. In addition, we demonstrated that
the HepaRG-AMC-BAL. prolongs the life of ALF rats substan-
tially with ,50%.
BAL culture increased hepatic differentiation of liver progenitor
cell line HepaRG, particularly its detoxification functionality.
CYP3A4 mRNA levels reached 88% of human liver in the
2DMSO BALs, whereas this level was only 10% in 2DMSO
monolayer cultures and ,70% in the presence of DMSO [16].
Hence, DMSO addition becomes superfluous for the upregulation
of detoxification functionality of HepaRG cells cultured in the
AMC-BAL, as opposed to HepaRG cells cultured in monolayer.
This is possibly related to the increased amount of cell-cell contacts
that result from the 3D culture environment of the AMC-BAL.
Interestingly, a high amount of cell-cell contacts is a prerequisite
for high CYP3A4 expression and activity in freshly isolated human
hepatocytes [23].
In our study, DMSO addition to the culture medium had
paramount negative effects on the functionality of HepaRG-
AMC-BALs as a whole, probably primarily due to massive
(,75%) cell death. On the cellular level, the effects of DMSO
were more ambiguous; on the one hand additional negative
effects unexplained by cell death, e.g. lactate consumption
switching into production and additional .2-fold decreased
Figure 4. Hepatic functions of the 2DMSO and +DMSO HepaRG-AMC-BALs. Ammonia elimination (A), total urea production (B),
15N-urea
production (C), 6b-hydroxytestosterone production (D), apolipoprotein A-1 production (E), and lactate consumption (F) of 2DMSO and +DMSO
HepaRG-AMC-BALs expressed ‘per BAL’ (white bars; read along the left y-axis) and ‘per mg of DNA’ (grey bars; read along the right y-axis).
Percentages depicted in the bars represent the percentage of this function of freshly isolated porcine hepatocytes cultured in the AMC-BAL (A, B, F)
and corrected for the amount of loaded cell pellet, or of freshly isolated human hepatocytes cultured on monolayer (D, E), or the percentage mass-
enriched urea of the total amount of produced urea in 24 hours (C). Values are expressed as means 6 standard deviations (n=5 to 11). Significance:
* P,0.05 versus 2DMSO group.
doi:10.1371/journal.pone.0038778.g004
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15N-urea production,
with, on the other hand increased HNF4a mRNA levels and a
trend towards increased PXR and CYP 3A4 mRNA levels. The
mechanism behind the differential effects of DMSO on cell
functions is unknown, but might be related to its pleiotropic
effect [14,24,25]. Proposedly, DMSO exerts its differentiating
actions by inducing cessation of the cell cycle and hyperacetyla-
tion of histones. In addition, DMSO is an inducer of several
phase I, II and III drug metabolizing enzymes in hepatocytes
including CYP3A4 [26]. On the other hand, DMSO represses
various other hepatic functions (e.g. expression urea cycle genes)
of cluster-neighbouring cells in HepaRG monolayer cultures
[16,27], perhaps due to differential susceptibility of HepaRG
cluster cells (with high CYP3A4 expression) versus cluster-
neighbouring cells to DMSO toxicity.
In vitro characterization of HepaRG-AMC-BALs demonstrated
that this cell line displays a level of high hepatic functionality [28].
Nonetheless, further improvements of the HepaRG-AMC-BAL
can be envisaged. For example, the rate of ammonia elimination
was over 50-fold higher than the rate of
15N-urea production,
despite the addition of N-carbamoyl-L-glutamate to the culture
medium. The metabolic fates of ammonia in the liver comprise
either conversion into urea or fixation into the amino acids
(glutamine and/or glutamate). As the expression of GS was over
400% the level of human liver, it is likely that the majority of
eliminated ammonia was converted into glutamine. Glutamine in
Figure 5. Efficacy of HepaRG-AMC-BAL treatment of rats with ALF. Efficacy was demonstrated by a significantly increased survival time
(P=0.001) (A), the median clinical grading score for HE (B), increased time to reach clinical HE score 4 (P=0.005) (C), lower blood ammonia levels (D),
and lower plasma creatinine levels (E). Continuous lines indicate the control group and dotted lines indicate the experimental group. Values are
expressed as median scores (B), or means 6 standard deviations (D, E) (n=5 to 6). Significance: * P,0.05 versus control group.
doi:10.1371/journal.pone.0038778.g005
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and thereby contributes to the progression of HE [29]. For this
reason, urea production is the preferred route for ammonia
elimination. The limited conversion of ammonia into urea in the
HepaRG-AMC-BAL is probably at least partly related to the low
expression levels of the urea cycle enzymes carbamoyl phosphate
synthetase, arginase 1, and ornithine transcarbamoylase [16]. Therefore,
overexpressing these genes in HepaRG cells would be an
interesting strategy to increase urea production.
It is difficult to speculate how an increase of ,50% in survival
time in our rat model of ALF would translate to a clinical setting of
patients with ALF. However, it is important to note that, unlike in
most clinical cases of ALF, the rats have no remnant liver function
in our model and the HepaRG-AMC-BALs contained the
equivalent of about 15%–20% of the normal total hepatocyte
mass of a rat liver. This amount is too low to provide stand-alone,
stable, and adequate liver support. In addition our model leads to
instant and complete necrosis of the liver, eliciting massive
inflammation. Notably however, our study was not devised to
predict the duration of liver supporting capacity in a clinical
setting, but to demonstrate the proof of principle that HepaRG-
AMC-BAL therapy is efficacious in rats with ALF. To put the
results of this study in perspective to BALs that use freshly isolated
hepatocytes (the golden standard), the AMC-BAL using freshly
isolated porcine hepatocytes as biocomponent is capable of
increasing the lifespan of rats with ALF ,2-fold using the same
model of CLI [7]. However, this porcine hepatocyte BAL
contained the double amount of bioactive mass compared to the
HepaRG-AMC-BAL in this study, rendering comparison difficult.
Notably, this difference in loading mass is caused by the ability of
porcine hepatocytes to attach to the oxygen capillaries, while
HepaRG cell solely attach to fibers of the matrix.
In conclusion, we have devised a human cell-based BAL using
the liver progenitor cell line HepaRG as biocomponent: the
HepaRG-AMC-BAL has a high and broad level of hepatic
functionality and has proven efficacy in a rat model of ALF. These
results encourage us to test the efficacy of the HepaRG-AMC-BAL
in a clinical trial in patients with ALF or acute-on-chronic liver
failure.
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